Total Payments
$1.2M
2024 Payments
$125,262
Companies
24
Transactions
1,171
Medicare Patients
146
Medicare Billing
$93,762
Payment Breakdown by Category
Other$957,980 (80.1%)
Travel$150,341 (12.6%)
Consulting$62,558 (5.2%)
Food & Beverage$24,530 (2.1%)
Research$417.00 (0.0%)
Education$81.98 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $957,980 | 242 | 80.1% |
| Travel and Lodging | $150,341 | 460 | 12.6% |
| Consulting Fee | $62,558 | 24 | 5.2% |
| Food and Beverage | $24,530 | 442 | 2.1% |
| Unspecified | $417.00 | 1 | 0.0% |
| Education | $81.98 | 2 | 0.0% |
Payments by Type
General
$1.2M
1,170 transactions
Research
$417.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $479,208 | 521 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $312,173 | 247 | $0 (2024) |
| Astellas Pharma US Inc | $173,960 | 155 | $0 (2024) |
| Kite Pharma, Inc. | $157,055 | 126 | $0 (2024) |
| Merck Sharp & Dohme LLC | $59,781 | 59 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $5,564 | 17 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $4,030 | 2 | $0 (2023) |
| National Marrow Donor Program | $2,800 | 9 | $0 (2024) |
| Celgene Corporation | $457.49 | 3 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $136.41 | 7 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $125,262 | 109 | Astellas Pharma US Inc ($34,922) |
| 2023 | $167,472 | 180 | Incyte Corporation ($55,093) |
| 2022 | $184,338 | 162 | Kite Pharma, Inc. ($65,683) |
| 2021 | $98,709 | 81 | JAZZ PHARMACEUTICALS INC. ($44,502) |
| 2020 | $93,995 | 69 | Incyte Corporation ($39,692) |
| 2019 | $269,551 | 288 | Incyte Corporation ($128,178) |
| 2018 | $165,611 | 181 | Incyte Corporation ($108,912) |
| 2017 | $90,969 | 101 | Incyte Corporation ($32,028) |
All Payment Transactions
1,171 individual payment records from CMS Open Payments — Page 45 of 47
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/09/2017 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $165.52 | General |
| Category: Hematology/Oncology | ||||||
| 11/09/2017 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Hematology/Oncology | ||||||
| 11/09/2017 | Merck Sharp & Dohme Corporation | NOXAFIL (Drug) | Travel and Lodging | Cash or cash equivalent | $25.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/07/2017 | Merck Sharp & Dohme Corporation | NOXAFIL (Drug) | Food and Beverage | In-kind items and services | $124.36 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/01/2017 | Jazz Pharmaceuticals Inc. | VYXEOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,410.00 | General |
| Category: Oncology | ||||||
| 11/01/2017 | Jazz Pharmaceuticals Inc. | VYXEOS (Drug) | Travel and Lodging | In-kind items and services | $706.91 | General |
| Category: Oncology | ||||||
| 11/01/2017 | Jazz Pharmaceuticals Inc. | VYXEOS (Drug) | Food and Beverage | In-kind items and services | $100.82 | General |
| Category: Oncology | ||||||
| 10/26/2017 | Jazz Pharmaceuticals Inc. | VYXEOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: Oncology | ||||||
| 10/26/2017 | Jazz Pharmaceuticals Inc. | VYXEOS (Drug) | Travel and Lodging | In-kind items and services | $1,370.19 | General |
| Category: Oncology | ||||||
| 10/26/2017 | Jazz Pharmaceuticals Inc. | VYXEOS (Drug) | Travel and Lodging | In-kind items and services | $213.57 | General |
| Category: Oncology | ||||||
| 10/26/2017 | Jazz Pharmaceuticals Inc. | VYXEOS (Drug) | Food and Beverage | In-kind items and services | $105.18 | General |
| Category: Oncology | ||||||
| 10/17/2017 | Jazz Pharmaceuticals Inc. | VYXEOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,200.00 | General |
| Category: Oncology | ||||||
| 10/17/2017 | Jazz Pharmaceuticals Inc. | VYXEOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,300.00 | General |
| Category: Oncology | ||||||
| 10/11/2017 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,440.00 | General |
| Category: Hematology/Oncology | ||||||
| 10/11/2017 | EMD Serono, Inc. | Bavencio (Biological) | Food and Beverage | Cash or cash equivalent | $16.70 | General |
| Category: Oncology | ||||||
| 10/10/2017 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $16.87 | General |
| Category: Hematology/Oncology | ||||||
| 10/03/2017 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Hematology/Oncology | ||||||
| 09/20/2017 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,660.00 | General |
| Category: Hematology/Oncology | ||||||
| 09/20/2017 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,440.00 | General |
| Category: Hematology/Oncology | ||||||
| 09/19/2017 | Jazz Pharmaceuticals Inc. | VYXEOS (Drug) | Food and Beverage | In-kind items and services | $115.08 | General |
| Category: Oncology | ||||||
| 09/14/2017 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $545.47 | General |
| Category: Hematology/Oncology | ||||||
| 09/14/2017 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $118.54 | General |
| Category: Hematology/Oncology | ||||||
| 09/07/2017 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $903.76 | General |
| Category: Hematology/Oncology | ||||||
| 09/07/2017 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Hematology/Oncology | ||||||
| 08/30/2017 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,660.00 | General |
| Category: Hematology/Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RV-MM-PI-0458 | Celgene Corporation | $417.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 54 | 340 | $72,120 | $34,189 |
| 2022 | 2 | 28 | 137 | $29,240 | $12,677 |
| 2021 | 2 | 41 | 292 | $57,495 | $26,733 |
| 2020 | 1 | 23 | 227 | $43,130 | $20,162 |
Total Patients
146
Total Services
996
Medicare Billing
$93,762
Procedure Codes
7
All Medicare Procedures & Services
7 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 30 | 293 | $55,670 | $29,195 | 52.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 24 | 47 | $16,450 | $4,995 | 30.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 15 | 111 | $21,090 | $9,605 | 45.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 13 | 26 | $8,150 | $3,072 | 37.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 28 | 261 | $49,590 | $22,950 | 46.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 13 | 31 | $7,905 | $3,783 | 47.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 23 | 227 | $43,130 | $20,162 | 46.7% |
About Dr. Usama Gergis, MD
Dr. Usama Gergis, MD is a Hematology & Oncology healthcare provider based in Allentown, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2007. The National Provider Identifier (NPI) number assigned to this provider is 1548450984.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Usama Gergis, MD has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $125,262 received in 2024. These payments were reported across 1,171 transactions from 24 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($957,980).
As a Medicare-enrolled provider, Gergis has provided services to 146 Medicare beneficiaries, totaling 996 services with total Medicare billing of $93,762. Data is available for 4 years (2020–2023), covering 7 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Allentown, PA
- Active Since 08/01/2007
- Last Updated 10/28/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1548450984
Products in Payments
- JAKAFI (Drug) $416,880
- DEFITELIO (Drug) $154,561
- VYXEOS (Drug) $152,845
- Yescarta (Drug) $146,796
- XOSPATA (Drug) $112,102
- Xospata (Drug) $54,768
- NOXAFIL (Drug) $39,701
- PREVYMIS (Drug) $18,457
- SPRYCEL (Drug) $4,000
- KYMRIAH (Biological) $2,973
- PROMACTA (Drug) $2,084
- NIKTIMVO (Drug) $685.00
- Revlimid (Drug) $457.49
- KYMRIAH (Drug) $383.44
- Orserdu (Drug) $125.46
- DIFICID (Drug) $123.04
- APHEXDA (Drug) $119.09
- Rezurock (Drug) $78.99
- Imbruvica (Drug) $77.69
- Defitelio (Drug) $76.73
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Allentown
Ranju Gupta
Hematology & Oncology — Payments: $35,823
Hematology & Oncology $35,823
Dr. Basil Ahmed, M.d, M.D
Hematology & Oncology — Payments: $20,659
Hematology & Oncology $20,659
Dr. Dan Popescu, M.d, M.D
Hematology & Oncology — Payments: $11,467
Hematology & Oncology $11,467
Dr. Mohammad Kazemi, M.d, M.D
Hematology & Oncology — Payments: $5,938
Hematology & Oncology $5,938
Tara Morrison, Md, MD
Hematology & Oncology — Payments: $5,415
Hematology & Oncology $5,415
Chun Siu, Do, DO
Hematology & Oncology — Payments: $3,115
Hematology & Oncology $3,115